Moreover, we found that considering the overexpression of MEK5 mRNA in addition to ERK5, as an indicator of the MEK5-ERK5 signaling axis, associated with poorer RFS and DMFS in basal-like breast cancer who received chemotherapy (Table 1B and Figure 1A). This evidence concerns the gene MAP2K5 and breast cancer.